



China Summit 2010

Pharma Manufacturing

—New Landscape Of Pharmaceutical Manufacturing In China

OCT. 12 -13, 2010 | InterContinental Hotel Shanghai | China

2010 Highlights & Reviews

- **Strategical topics for the local and oversea pharmaceutical manufacturing giants**
- **Global manufacturer - outsourcing concern and criteria?**
- **Supporting the sustainable Implementation of operational excellence**
- **Local manufacturer's 3- 5 years capacity strategy - how to moving up the value chain?**
- **China latest drug reform, new GMP standard and technology transfer issues**
- **Facilitating and Achieving QbD for drug products.**
- **Green manufacturing strategies - Harnessing the opportunities for cost reduction.**
- **PAT, process Improvement and cost reduction.**
- **Developing a flexible, multi-product manufacturing strategy.**
- **Creating the pharmaceutical facility of the future.**

In 2009, AstraZeneca announced the company would further expand its supplying base in Wuxi and have more products locally produced in China.

In 2009, Eli Lilly unveiled an over 40 million USD investment for expanding its facility in Suzhou, Jiangsu Province, China. With an area of 50,000 sqm, the expanded facility will manufacture Lilly's insulin products, a function separate from the old facility which will be utilized fully for producing the cephalosporin formulations of Lilly.

In 2009, Sanofi-aventis announced that the company will relocate its current manufacturing facility from downtown Hangzhou and build a new manufacturing site in Binjiang New Development Zone. Involving an investment of 270 million RMB (31 million Euro), the new site is scheduled to be completed by 2012 and have an expanded capacity of 160 million packs. With an area of 44,775 square meters, the new site also allows the potential for further expansion and the creation of an export hub to other Asian countries.

In 2009, Sanofi-aventis announced an increase of capital investment in the amount of US\$90 million (RMB 600 million) to extend its current manufacturing facility located at the Beijing Economic and Technological Development Area, and to build pre-filled injection production lines for Lantus® (Insulin Glargine) SoloSTAR®.

New GMP standard, manufacturing facility project, pharmaceutical synthesis process, QA/QS, packaging, automation, PAT, Part 11, pharmaceutical water system, API & CMO and other innovative technologies will be discussed in this event.

Furthermore, we would bring you some proactive thoughts on how to screen out qualified local partners? Any update regulations by state? What are the advantages in manufacturing China? Where is the best location for your plant? Beijing, Tianjin or Shanghai?

Distinguished Speakers



Invited Companies

Oversea Companies

Johnson and Johnson
 Pfizer
 Bayer
 GlaxoSmithKline
 Novartis
 Sanofi-Aventis
 Hoffmann-La Roche
 AstraZeneca
 Merck & Co.
 Abbott Laboratories
 Wyeth
 Bristol-Myers Squibb
 Eli Lilly and Company
 Amgen
 Boehringer Ingelheim
 Schering-Plough
 Baxter International
 Takeda Pharmaceutical Co.
 Genentech
 Procter & Gamble
 Teva Pharmaceutical Industries
 Astellas Pharma
 Daiichi Sankyo
 Novo Nordisk
 Eisai
 Merck KGaA
 Alcon
 SINOPHARM
 Akzo Nobel
 UCB
 Nycomed
 Forest Laboratories
 Solvay
 Allergan
 Gilead Sciences
 CSL

Chugai Pharmaceutical Co.
 Biogen Idec
 Bausch & Lomb
 Taiho Pharmaceutical Co.
 King Pharmaceuticals
 Watson Pharmaceuticals
 Mitsubishi Pharma
 Shire

...

Domestic Companies

Shanghai Pharmaceutical Group Co.
 China Pharmaceutical Group Central Co Ltd.
 Guangzhou Medical Group Co Ltd.
 Tranjin Medical Group Co Ltd.
 Shandong Dongde Donkey-hide Gelatin Co.,Ltd
 Harbin Medical Group Co Ltd.
 Nanjing Pharmaceutical Industry Group Co Ltd.
 North China Pharmaceutical Group Co Ltd.
 Jiangsu Yangzi River Pharmaceutical Group Co Ltd.
 China Nepstar
 Harbin Pharmaceutical Group Co., Ltd.
 Jilin Aodong Medicine
 China National Pharmaceutical Group
 Taiji Group Co Ltd.
 CSPC Zhongrun
 China Greatvista Chemicals Corporation
 China National Pharmaceutical Industry Corporation

Limited(abbreviated as CNPIC)
 Beijing Double-Crane Pharmaceutical Co., Ltd.
 (DCPC)
 Beijing Second Pharmaceutical Co., Ltd. (BSPC)
 Beijing Yimin pharmaceutical Co.,Ltd
 Guangzhou Baiyunshan Pharmaceutical Co., Ltd.
 China national pharmaceutical industry corporation ltd.
 Lunan Pharmaceutical Group Corporation
 Tianjing lisheng pharmaceutical co.,ltd.
 Tianjing huajin pharmaceutical Lijun International Pharmaceutical (Holding) Co. Ltd.
 Nanjing Ange Pharmaceutical
 North China Pharmaceutical Group Corp
 Shijiazhuang Pharma Group
 Simcere Pharmaceutical
 Changchun GeneScience Pharmaceutkal
 Tonghua Dongbao Pharmaceutical Group
 Hangzhou Jiuyuan Gene Engineering
 Shanghai CP Guojian Pharmaceutical
 Beijing Yuance Pharmaceutical
 Changchun BCHT Pharmaceutical
 China National Biotec Group(CNBG)

Chengdu Rongsheng
Pharmaceutical
Sichuan Yuanda Shuyang
Pharmaceutical
Shanghai Xinxing Medicine
...

More details please contact:

Terry KIM

Production Executive

Tel: +86 21 5058 9600 Fax: +86 21 5058 5987

Email: t.kim@opplandcorp.com

OPPLAND Corporation 2102-2103, Suncome Liauw's Plaza, 738 Shangcheng Road, Shanghai, 200120 CHINA